103.87 - 102.25
59.8 - 105.69
Join Discuss about NVO with like-minded investors
$NVO-Bullish option flow detected in Novo Nordisk (103.15 +2.97) with 15,028 calls trading (11x expected) and implied vol increasing over 1 point to 36.81%. . The Put/Call Ratio is 0.31. Earnings are expected on 11/01. The NOV 17th 115 Calls are being bought.
149 Replies 7 👍 13 🔥
Top Earnings Th 5/4 Pre: $ABUS $ACIW $AEP $AGIO $ALCO $ALNY $AMTX $AOMR $APG $APRN $APTV $ARGX $ARHS $ARNC $ARW $ATI $AUPH $BALL $BCE $BDX $BERY $BHC $BKI $BKTI $BLD $BPMC $BRKR $BSIG $BUD $BV $BVH $BWA $CAH $CARS $CCLD $CCLP $CCOI $CCRD $CEG $CG $CGNX $CIM $CLDT (1/5) Top Earnings Th 5/4 Pre: $CMRX $CNQ $COMM $COP $CRAI $CWEN $DCO $DDOG $DGII $DINO $DLX $DNB $DNOW $DOC $DSGR $DTC $DXYN $ECVT $ENOV $EQNR $ESMT $EVA $FOCS $FOUR $FTDR $FUN $GCI $GECC $GEL $GHI $GLT $GOLF $GPP $GPRE $GTES $H $HAYW $HEP $HII $IBP $ICE $IDA (2/5) Top Earnings Th 5/4 Pre: $IDCC $IMOS $IMXI $INFU $INSM $IRM $IRMD $IRWD $ITCI $ITRI $ITT $JLL $K $KPTI $KRTX $KTB $KYMR $LAMR $LANC $LAUR $LEE $LNTH $LQDA $LQDT $MAC $MCS $MDU $MFA $MGPI $MLM $MMP $MNTX $MODV $MPLN $MRNA $MSGS $MT $MTSI $MYE $NFE $NJR $NRG (3/5) Top Earnings Th 5/4 Pre: $NRP $NS $NTCT $NTLA $NVCR $NVO $NWN $NXE $OCN $OCSL $OGE $OGN $ONEW $OPCH $OWL $PACK $PARA $PARAA $PAX $PBH $PCG $PENN $PH $PLNT $PLTK $PLX $PLYM $PNW $PPL $PRMW $PRVA $PTLO $PTON $PWP $PWR $PZZA $RACE $RCL $RCM $REGN $RITM $SABR $SBH (4/5) Top Earnings Th 5/4 Pre: $SCU $SELB $SHAK $SHEL $SPH $SRE $SSRM $STVN $STWD $SUP $SWK $SXC $TCPC $TELNY $TFX $TGLS $THRY $TIXT $TRGP $TTSH $TU $UNIT $UPBD $VEON $VIA $VITL $VMC $VNT $W $WBX $WCC $WD $WLK $WLKP $WOW $WRK $WRLD $XFOR $XPO $XPRO $XTNT $XYL $ZTS (5/5)
47 Replies 9 👍 8 🔥
Upgrades 4/13: $BX $CFRX $CVX $DKNG $EOG $INGR $MNTK $MRK $NVO $SHOO $SPWR $VFC $WWE .. Downgrades 4/13: $BRFS $CUBE $FSLR $JD $LSI $LXU $LYB $NATI $NSA $PKX $PLTK $SPWH $TESS $TRTN $XOM +Initiations 4/13: $AVGO $CCCS $COST $CRSP $ENPH $FTCI $MGNI $NTLA $PLRX $PRI $PUBM $RLAY $RXST $SEDG $SNAL $VERV .. -Initiations 4/13:
53 Replies 15 👍 6 🔥
$NVO The drug, semaglutide, made by Novo Nordisk, already is marketed as a treatment for Type 2 diabetes. In a clinical trial published in the New England Journal of Medicine, researchers at Northwestern University in Chicago tested semaglutide at a much higher dose as an anti-obesity medication.
78 Replies 14 👍 13 🔥
nvo hardely moves
119 Replies 15 👍 10 🔥
Going to gamble on a small lot of NVO 21AUG $65 calls
94 Replies 7 👍 8 🔥
Next Dividend Date
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
CEO: Lars Fruergaard Joergensen
HQ: Novo Alle, 2880 Bagsvaerd